2023年度非小细胞肺癌放射治疗研究进展

Advance in non-small cell lung cancer radiotherapy in 2023

肺癌是我国发病率和死亡率最高的恶性肿瘤,根据病理及细胞学肺癌可分为非小细胞肺癌(non-small cell lung cancer,NSCLC)及小细胞肺癌,其中NSCLC约占85%。晚期NSCLC患者预后差,放射治疗和化疗是主要的治疗手段,但随着放射治疗技术的创新和免疫治疗、靶向治疗的发展,在不同时期NSCLC的放射治疗模式逐渐呈现出新的格局。本文旨在介绍2023年度NSCLC放射治疗领域的研究进展。

Lung cancer is the malignant tumor with the highest incidence of morbidity and mortality in China.According to pathology and cytology,lung cancer can be divided into non-small cell lung cancer(NSCLC)and small cell lung cancer,among which NSCLC accounts for about 85%.The prognosis of patients with advanced NSCLC disease is poor,and radiotherapy and chemotherapy are the main therapeutic methods.However,with the innovation of radiotherapy technology and the development of immunotherapy and targeted therapy,the radiotherapy mode of NSCLC gradually presents a new pattern in different periods.This paper aims to present the research progress in the field of radiotherapy in NSCLC in 2023.